ID   A-431
AC   CVCL_0037
SY   A431; A431/P
DR   BTO; BTO:0000017
DR   CLO; CLO_0001591
DR   CLO; CLO_0001592
DR   CLO; CLO_0050011
DR   CLO; CLO_0050012
DR   EFO; EFO_0006268
DR   MCCL; MCC:0000025
DR   CLDB; cl155
DR   CLDB; cl156
DR   CLDB; cl157
DR   CLDB; cl159
DR   CLDB; cl160
DR   CLDB; cl161
DR   Abcam; ab263975
DR   Abcam; ab275462
DR   AddexBio; C0012001/22
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CRL-1555
DR   ATCC; CRL-7907
DR   BCRC; 60161
DR   BCRJ; 0032
DR   BioGRID_ORCS_Cell_line; 1572
DR   BioSample; SAMN01821614
DR   BioSample; SAMN01821671
DR   BioSample; SAMN01821724
DR   BioSample; SAMN03472220
DR   cancercelllines; CVCL_0037
DR   CCRID; 1101HUM-PUMC000092
DR   CCRID; 3101HUMTCHu188
DR   CCRID; 4201HUM-CCTCC00084
DR   Cell_Model_Passport; SIDM00995
DR   ChEMBL-Cells; CHEMBL3307523
DR   ChEMBL-Targets; CHEMBL614069
DR   CLS; 300112
DR   Cosmic; 688038
DR   Cosmic; 735609
DR   Cosmic; 755305
DR   Cosmic; 876559
DR   Cosmic; 897743
DR   Cosmic; 910564
DR   Cosmic; 910925
DR   Cosmic; 974317
DR   Cosmic; 1071898
DR   Cosmic; 1176624
DR   Cosmic; 1351516
DR   Cosmic; 1477434
DR   Cosmic; 1945879
DR   Cosmic; 1995334
DR   Cosmic; 2131571
DR   Cosmic; 2301592
DR   Cosmic; 2646654
DR   Cosmic-CLP; 910925
DR   DepMap; ACH-001328
DR   DSMZCellDive; ACC-91
DR   ECACC; 85090402
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 910925
DR   GEO; GSM183432
DR   GEO; GSM183433
DR   GEO; GSM827302
DR   GEO; GSM1374384
DR   GEO; GSM1669586
DR   GEO; GSM2112551
DR   GEO; GSM2112555
DR   IARC_TP53; 21167
DR   IARC_TP53; 23618
DR   JCRB; IFO50411
DR   KCB; KCB 200651YJ
DR   KCLB; 21555
DR   KCLB; 80005
DR   Lonza; 814
DR   NCBI_Iran; C204
DR   PharmacoDB; A431_46_2019
DR   PRIDE; PXD000065
DR   PRIDE; PXD000589
DR   PRIDE; PXD000681
DR   PRIDE; PXD001582
DR   PRIDE; PXD003937
DR   PRIDE; PXD006291
DR   PRIDE; PXD005301
DR   PRIDE; PXD007206
DR   PRIDE; PXD008996
DR   PRIDE; PXD017536
DR   PRIDE; PXD030304
DR   PRIDE; PXD030984
DR   PRIDE; PXD033685
DR   Progenetix; CVCL_0037
DR   PubChem_Cell_line; CVCL_0037
DR   RCB; RCB0202
DR   RCB; RCB1872
DR   TKG; TKG 0182
DR   TOKU-E; 476
DR   Ubigene; YC-D016
DR   Wikidata; Q4649310
RX   PubMed=212188;
RX   PubMed=1394225;
RX   PubMed=2228902;
RX   PubMed=2758419;
RX   PubMed=2990217;
RX   PubMed=4357758;
RX   PubMed=6092175;
RX   PubMed=6254071;
RX   PubMed=6500159;
RX   PubMed=6954533;
RX   PubMed=6983291;
RX   PubMed=9290701;
RX   PubMed=9887230;
RX   PubMed=11416159;
RX   PubMed=11668190;
RX   PubMed=17178626;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22108792;
RX   PubMed=22282976;
RX   PubMed=23637631;
RX   PubMed=24804581;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=26989177;
RX   PubMed=27397505;
RX   PubMed=28176443;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   Population: Caucasian.
CC   Doubling time: ~80-100 hours (DSMZ=ACC-91).
CC   HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02 (PubMed=25960936).
CC   HLA typing: A*03:01,03:01; B*07:02,07:02; C*07:02,07:02; DRB1*11:04,12:01 (PubMed=26589293).
CC   Karyotypic information: Hypertriploid karyotype (ATCC=CRL-1555).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 3236; EGFR + HGNC; 9237; PPARGC1A; Name(s)=EGFR-PPARGC1A (PubMed=23637631).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Unspecified (PubMed=1394225).
CC   Omics: Cell surface proteome.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=3.82%; Native American=0%; East Asian, North=7.84%; East Asian, South=0%; South Asian=6.03%; European, North=17.15%; European, South=65.16% (PubMed=30894373).
CC   Discontinued: ATCC; CRL-7907; true.
CC   Derived from site: In situ; Skin, epidermis; UBERON=UBERON_0001003.
ST   Source(s): AddexBio=C0012001/22; ATCC=CRL-1555; CCRID; CLS=300112; Cosmic-CLP=910925; DepMap=ACH-001328; DSMZ=ACC-91; Technion Genomics Center BCF; IZSLER=BS TCL 161; JCRB=IFO50411; JCRB=JCRB0004; KCLB=21555; KCLB=80005; PubMed=11416159; PubMed=25877200; RCB=RCB0202; RCB=RCB1872; TKG=TKG 0182
ST   Amelogenin: X (ATCC=CRL-1555; CCRID; CLS=300112; Cosmic-CLP=910925; DepMap=ACH-001328; DSMZ=ACC-91; Technion Genomics Center BCF; IZSLER=BS TCL 161; JCRB=IFO50411; JCRB=JCRB0004; KCLB=21555; PubMed=11416159; PubMed=25877200; RCB=RCB0202; RCB=RCB1872; TKG=TKG 0182)
ST   Amelogenin: X,Y (AddexBio=C0012001/22)
ST   CSF1PO: 11,12
ST   D10S1248: 13,15
ST   D12S391: 18,23
ST   D13S317: 9,13
ST   D16S539: 12,14
ST   D18S51: 13,17
ST   D19S433: 15,15.2 (ATCC=CRL-1555; CCRID; Technion Genomics Center BCF)
ST   D19S433: 15,16 (DSMZ=ACC-91)
ST   D1S1656: 16,17
ST   D21S11: 28 (ATCC=CRL-1555; CCRID; DepMap=ACH-001328; Technion Genomics Center BCF; IZSLER=BS TCL 161; PubMed=25877200)
ST   D21S11: 28,30 (CLS=300112; DSMZ=ACC-91; PubMed=11416159)
ST   D22S1045: 15,16
ST   D2S1338: 17,20
ST   D2S441: 11.3,15
ST   D3S1358: 14 (ATCC=CRL-1555; CLS=300112; DepMap=ACH-001328; DSMZ=ACC-91; KCLB=21555; KCLB=80005; Technion Genomics Center BCF; PubMed=25877200)
ST   D3S1358: 14,20 (CCRID)
ST   D5S818: 11,13 (AddexBio=C0012001/22)
ST   D5S818: 12,13 (ATCC=CRL-1555; CCRID; CLS=300112; Cosmic-CLP=910925; DepMap=ACH-001328; DSMZ=ACC-91; Technion Genomics Center BCF; IZSLER=BS TCL 161; JCRB=IFO50411; JCRB=JCRB0004; KCLB=21555; KCLB=80005; PubMed=25877200; RCB=RCB0202; RCB=RCB1872; TKG=TKG 0182)
ST   D7S820: 10
ST   D8S1179: 13
ST   FGA: 20
ST   Penta D: 9,11 (CLS=300112; DSMZ=ACC-91)
ST   Penta D: 11 (ATCC=CRL-1555; DepMap=ACH-001328; Technion Genomics Center BCF; PubMed=25877200)
ST   Penta E: 12,13
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 15,17
DI   NCIt; C4819; Skin squamous cell carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   85Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 48
RX   PubMed=212188;
RA   Todaro G.J., De Larco J.E.;
RT   "Growth factors produced by sarcoma virus-transformed cells.";
RL   Cancer Res. 38:4147-4154(1978).
RX   PubMed=1394225;
RA   Somers K.D., Merrick M.A., Lopez M.E., Incognito L.S., Schechter G.L.,
RA   Casey G.;
RT   "Frequent p53 mutations in head and neck cancer.";
RL   Cancer Res. 52:5997-6000(1992).
RX   PubMed=2228902; DOI=10.1007/BF02624609;
RA   Rikimaru K., Toda H., Tachikawa N., Kamata N., Enomoto S.;
RT   "Growth of the malignant and nonmalignant human squamous cells in a
RT   protein-free defined medium.";
RL   In Vitro Cell. Dev. Biol. 26:849-856(1990).
RX   PubMed=2758419;
RA   Pekkola-Heino K., Kulmala J., Grenman S.E., Carey T.E., Grenman R.;
RT   "Radiation response of vulvar squamous cell carcinoma (UM-SCV-1A,
RT   UM-SCV-1B, UM-SCV-2, and A-431) cells in vitro.";
RL   Cancer Res. 49:4876-4878(1989).
RX   PubMed=2990217;
RA   Yee C., Krishnan-Hewlett I., Baker C.C., Schlegel R., Howley P.M.;
RT   "Presence and expression of human papillomavirus sequences in human
RT   cervical carcinoma cell lines.";
RL   Am. J. Pathol. 119:361-366(1985).
RX   PubMed=4357758; DOI=10.1093/jnci/51.5.1417;
RA   Giard D.J., Aaronson S.A., Todaro G.J., Arnstein P., Kersey J.H.,
RA   Dosik H., Parks W.P.;
RT   "In vitro cultivation of human tumors: establishment of cell lines
RT   derived from a series of solid tumors.";
RL   J. Natl. Cancer Inst. 51:1417-1423(1973).
RX   PubMed=6092175; DOI=10.1016/0303-7207(84)90053-4;
RA   Gamou S., Kim Y.S., Shimizu N.;
RT   "Different responses to EGF in two human carcinoma cell lines, A431
RT   and UCVA-1, possessing high numbers of EGF receptors.";
RL   Mol. Cell. Endocrinol. 37:205-213(1984).
RX   PubMed=6254071; DOI=10.1073/pnas.77.9.5258;
RA   Todaro G.J., Fryling C.M., De Larco J.E.;
RT   "Transforming growth factors produced by certain human tumor cells:
RT   polypeptides that interact with epidermal growth factor receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:5258-5262(1980).
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
RX   PubMed=6954533; DOI=10.1073/pnas.79.7.2194;
RA   Westin E.H., Gallo R.C., Arya S.K., Eva A., Souza L.M., Baluda M.A.,
RA   Aaronson S.A., Wong-Staal F.;
RT   "Differential expression of the amv gene in human hematopoietic
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 79:2194-2198(1982).
RX   PubMed=6983291; DOI=10.1002/aja.1001650207;
RA   Barka T., van der Noen H.M.;
RT   "Culture of A-431 human epidermoid carcinoma cells in serum-free
RT   medium: effect of culture conditions on the binding of
RT   [125I]-epidermal growth factor.";
RL   Am. J. Anat. 165:187-198(1982).
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
RX   PubMed=9887230; DOI=10.1006/gyno.1998.5194;
RA   Rantanen V., Grenman S.E., Kurvinen K., Hietanen S., Raitanen M.,
RA   Syrjanen S.M.;
RT   "p53 mutations and presence of HPV DNA do not correlate with
RT   radiosensitivity of gynecological cancer cell lines.";
RL   Gynecol. Oncol. 71:352-358(1998).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
RX   PubMed=17178626; DOI=10.1080/09553000600969812;
RA   Kurvinen K., Rantanen V., Syrjanen S.M., Johansson B.;
RT   "Radiation-induced effects on telomerase in gynecological cancer cell
RT   lines with different radiosensitivity and repair capacity.";
RL   Int. J. Radiat. Biol. 82:859-867(2006).
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=22108792; DOI=10.1038/msb.2011.84;
RA   Munoz J., Low T.Y., Kok Y.J., Chin A., Frese C.K., Ding V.,
RA   Choo A.B.-H., Heck A.J.R.;
RT   "The quantitative proteomes of human-induced pluripotent stem cells
RT   and embryonic stem cells.";
RL   Mol. Syst. Biol. 7:550-550(2011).
RX   PubMed=22282976; DOI=10.1093/carcin/1.1.21;
RA   Day R.S. III, Ziolkowski C.H.J., Scudiero D.A., Meyer S.A.,
RA   Mattern M.R.;
RT   "Human tumor cell strains defective in the repair of alkylation
RT   damage.";
RL   Carcinogenesis 1:21-32(1980).
RX   PubMed=23637631; DOI=10.1371/journal.pgen.1003464;
RA   Giacomini C.P., Sun S., Varma S., Shain A.H., Giacomini M.M.,
RA   Balagtas J.M.S., Sweeney R.T., Lai E., Del Vecchio C.A., Forster A.D.,
RA   Clarke N., Montgomery K.D., Zhu S., Wong A.J., van de Rijn M.,
RA   West R.B., Pollack J.R.;
RT   "Breakpoint analysis of transcriptional and genomic profiles uncovers
RT   novel gene fusions spanning multiple human cancer types.";
RL   PLoS Genet. 9:E1003464-E1003464(2013).
RX   PubMed=24804581; DOI=10.1021/cb500116c;
RA   Giansanti P., Preisinger C., Huber K.V.M., Gridling M.,
RA   Superti-Furga G., Bennett K.L., Heck A.J.R.;
RT   "Evaluating the promiscuous nature of tyrosine kinase inhibitors
RT   assessed in A431 epidermoid carcinoma cells by both chemical- and
RT   phosphoproteomics.";
RL   ACS Chem. Biol. 9:1490-1498(2014).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=26989177; DOI=10.1242/dev.133728;
RA   Elbediwy A., Vincent-Mistiaen Z.I., Spencer-Dene B., Stone R.K.,
RA   Boeing S., Wculek S.K., Cordero J., Tan E.H., Ridgway R.,
RA   Brunton V.G., Sahai E., Gerhardt H., Behrens A., Malanchi I.,
RA   Sansom O.J., Thompson B.J.;
RT   "Integrin signalling regulates YAP and TAZ to control skin
RT   homeostasis.";
RL   Development 143:1674-1687(2016).
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
RX   PubMed=28176443; DOI=10.1002/pmic.201600254;
RA   Tiwari R., Sahu I., Soni B.L., Sathe G.J., Datta K.K., Thapa P.,
RA   Sinha S., Vadivel C.K., Dhaka B., Gowda H., Vaidya M.M.;
RT   "Quantitative phosphoproteomic analysis reveals system-wide signaling
RT   pathways regulated by site-specific phosphorylation of keratin-8 in
RT   skin squamous cell carcinoma derived cell line.";
RL   Proteomics 17:1600254.1-1600254.17(2017).
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).